September 01, 2016 2:07 AM ET

Healthcare Equipment and Supplies

Company Overview of Sebacia, Inc.

Company Overview

Sebacia, Inc., a medical device company, focuses on creating light-based therapies for the treatment of dermatological conditions. It is developing a device for the treatment of acne. Sebacia, Inc. was formerly known as TIF Acquisition XII, Inc. The company was incorporated in 2008 and is based in Duluth, Georgia.

2905 Premiere Parkway

Suite 150

Duluth, GA 30097

United States

Founded in 2008

Phone:

678-417-7626

Fax:

678-417-7325

Key Executives for Sebacia, Inc.

Chief Executive Officer, President and Director
Executive Officer
Vice President of Engineering and Program Management
Compensation as of Fiscal Year 2016.

Sebacia, Inc. Key Developments

Sebacia, Inc. Announces Completion of Enrollment in Pivotal U.S. Clinical Trial for Severe Acne

Sebacia, Inc. announced completion of enrollment in the U.S. randomized pivotal clinical trial investigating the use of the Sebacia Acne Treatment System, an investigational device that uses a combination of gold microparticles and laser energy to target acne. Unlike acne treatments that require daily treatments with lotions or pills, the Sebacia System is intended to treat acne through a simple, physician-guided, in-office procedure. Sebacia's proprietary gold microparticles are designed to be used with existing dermatologic lasers to heat the sebaceous glands and follicles to treat acne. The pivotal clinical study is a randomized, blinded, controlled assessment to determine the safety and effectiveness of the Sebacia Acne Treatment System in the treatment of inflammatory acne vulgaris. A total of 396 people were enrolled with 28 dermatologists across the United States. The studies were designed as parallel assignment with one treatment group and two control groups. The control groups received either Sebacia microparticles without laser treatment or the suspension without Sebacia microparticles with laser treatment. Primary outcome measures are the mean percent change in inflammatory lesion count from baseline to week 12 and the safety and tolerability of the procedure. Secondary outcome measures are the mean absolute change in inflammatory lesion count from baseline to week 12 and success by investigator's global assessment (IGA) at week 12. Success is defined as a two-point decrease from baseline IGA. Although accrual is complete, follow up of participants will continue until December 2015.

Sebacia, Inc. Presents at Emerging Medical Technologies Summit, Oct-21-2015 10:00 AM

Sebacia, Inc. Presents at Emerging Medical Technologies Summit, Oct-21-2015 10:00 AM. Venue: Sofitel Hotel San Francisco, 223 Twin Dolphin Dr., Redwood City, CA 94065, United States.

Square 1 Bank Announces Credit Facility to Sebacia, Inc

Square 1 Bank announced that it has provided a $10 million credit facility to new client Sebacia, Inc. Proceeds will be used to support the company's continued growth.

Similar Private Companies By Industry

Company Name Region
.decimal, Inc. United States
20/20 GeneSystems, Inc. United States
20/20 Imaging LLC United States
21st Century Scientific, Inc. United States
21X Corporation United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Sebacia, Inc., please visit www.sebacia.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.